Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology

被引:36
作者
Im, Annie [1 ]
Appleman, Leonard J. [1 ]
机构
[1] Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15232 USA
关键词
mifepristone; misoprostol; progesterone; termination of pregnancy; LOW-DOSE MIFEPRISTONE; PROGESTERONE-RECEPTOR MODULATORS; EARLY-PREGNANCY FAILURE; PHASE-II; IN-VITRO; RU-486; RU486; LEVONORGESTREL; THERAPY; TRIAL;
D O I
10.1517/14656560903535880
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Mifepristone is a synthetic selective progesterone-receptor modulator (SPRM) that is widely used around the globe in the field of reproductive medicine. At present mifepristone is approved in a number of countries for early termination of pregnancy (TOP), cervical dilatation before surgical TOP, and management of early embryonic loss or fetal death. A number of new clinical applications are being developed in gynecology, endocrinology and oncology. Mifepristone has also served as an invaluable tool in the study of steroid hormone biology. Areas covered in this review: Current indications for mifepristone are reviewed. New applications for mifepristone under clinical investigation are discussed. In addition, the unique molecular and cellular effects of mifepristone are described. What the reader will gain: The reader will understand the mechanisms of action of mifepristone and the underlying steroid hormone biology. The reader will know the approved clinical indications for mifepristone and appreciate the ongoing basic and clinical research into new applications. Take home message: Mifepristone is the first-discovered and still most widely used antiprogestin. It has several indications in reproductive medicine and is under investigation for a variety of potential applications in other fields of medicine. The molecular and cellular effects of mifepristone illuminate important aspects of steroid hormone biology.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 53 条
[1]  
ABDELALEEM H, 2007, COCHRANE DB SYST REV, V4
[2]   Effect of long-term treatment with low-dose mifepristone on the endometrium [J].
Baird, DT ;
Brown, A ;
Critchley, HOD ;
Williams, AR ;
Lin, S ;
Cheng, L .
HUMAN REPRODUCTION, 2003, 18 (01) :61-68
[3]   Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone [J].
Belanoff, JK ;
Jurik, J ;
Schatzberg, LD ;
DeBattista, C ;
Schatzberg, AF .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 19 (1-2) :201-206
[4]  
Benagiano G, 2008, EXPERT OPIN PHARMACO, V9, P2487, DOI [10.1517/14656566.9.14.2487, 10.1517/14656566.9.14.2487 ]
[5]   A SINGLE AMINO-ACID THAT DETERMINES THE SENSITIVITY OF PROGESTERONE RECEPTORS TO RU486 [J].
BENHAMOU, B ;
GARCIA, T ;
LEROUGE, T ;
VERGEZAC, A ;
GOFFLO, D ;
BIGOGNE, C ;
CHAMBON, P ;
GRONEMEYER, H .
SCIENCE, 1992, 255 (5041) :206-209
[6]   A multisite trial of mifepristone for the treatment of psychotic depression: A site-by-treatment interaction [J].
Blasey, Christine M. ;
DeBattista, Charles ;
Roe, Robert ;
Block, Thaddeus ;
Belanoff, Joseph K. .
CONTEMPORARY CLINICAL TRIALS, 2009, 30 (04) :284-288
[7]   Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days [J].
Brown, A ;
Cheng, LN ;
Lin, SQ ;
Baird, DT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :63-70
[8]   DIFFERENTIAL GENE ACTIVATION BY GLUCOCORTICOIDS AND PROGESTINS THROUGH THE HORMONE REGULATORY ELEMENT OF MOUSE MAMMARY-TUMOR VIRUS [J].
CHALEPAKIS, G ;
ARNEMANN, J ;
SLATER, E ;
BRULLER, HJ ;
GROSS, B ;
BEATO, M .
CELL, 1988, 53 (03) :371-382
[9]   Medical management of early pregnancy failure: Efficacy [J].
Chen, Beatrice A. ;
Creinin, Mitchell D. .
SEMINARS IN REPRODUCTIVE MEDICINE, 2008, 26 (05) :411-422
[10]  
CHENG L, 2008, COCHRANE DB SYST REV, V2